Lv2
104 积分 2023-12-02 加入
Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study
12天前
已完结
Regulated necrosis at the crossroads of liver inflammation and cancer development
1个月前
已完结
The origin of hepatocellular carcinoma depends on metabolic zonation
1个月前
已完结
Improving surgical treatments for hepatocellular carcinoma
1个月前
已完结
Integrated therapies for targeting the microenvironment of hepatocellular carcinoma
1个月前
已完结
Advances in Locoregional and Systemic Treatments for Hepatocellular Carcinoma
1个月前
已完结
HAIC plus lenvatinib and tislelizumab for advanced hepatocellular carcinoma with Vp4 portal vein invasion
4个月前
已完结
The side effects of platinum-based chemotherapy drugs: a review for chemists
4个月前
已完结
Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival
4个月前
已完结
Combination of FDG-PET and UCSF Criteria for Predicting HCC Recurrence After Living Donor Liver Transplantation
4个月前
已完结
皖公网安备34019202002308
